Jiming Huang / Blog
Pivot (invalidation): 0.6800 Our preference Long positions above 0.6800 with targets at 0.6820 & 0.6835 in extension. Alternative scenario...
Pivot (invalidation): 1.3245 Our preference Short positions below 1.3245 with targets at 1.3215 & 1.3190 in extension. Alternative scenario...
Pivot (invalidation): 0.9860 Our preference Short positions below 0.9860 with targets at 0.9830 & 0.9820 in extension. Alternative scenario...
Pivot (invalidation): 108.65 Our preference Long positions above 108.65 with targets at 108.85 & 109.00 in extension. Alternative scenario...
Pivot (invalidation): 1.3160 Our preference Short positions below 1.3160 with targets at 1.3105 & 1.3070 in extension. Alternative scenario...
Pivot (invalidation): 1.1080 Our preference Long positions above 1.1080 with targets at 1.1105 & 1.1115 in extension. Alternative scenario...
Merck & Co. said it is buying ArQule Inc. for about $2.7 billion, adding to its portfolio of cancer treatments beyond the company's top-selling immunotherapy drug Keytruda. The purchase price, at $20 a share in cash, is more than double Friday's closing price of $9...
Global equities fell lower on Tuesday morning ahead of tomorrow FOMC meeting, with front month futures on the S&P 500 erasing Friday’s gains. The effect of the better than expected NFP figures didn’t last long. S&P futures are down 0...
Pivot (invalidation): 58.55 Our preference Long positions above 58.55 with targets at 59.50 & 59.85 in extension. Alternative scenario...